Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Atlanta, Georgia 30322


Purpose:

The purpose of this study is to learn whether or not giving a tetanus/diphtheria vaccination ("tetanus shot") before giving pneumococcal vaccine makes the pneumococcal vaccine more effective without causing too many side effects.


Study summary:

The only vaccine licensed in the United States for protecting adults against pneumococcal disease (PPV23) protects against invasive disease in observational studies but has generally been poorly effective against pneumonia or all-cause mortality in randomized clinical trials. Another vaccine containing seven polysaccharide antigens conjugated to diphtheria toxoid (PCV7) is licensed for children and under investigation in adults. In this pilot study, we are comparing the safety and immunogenicity of three immunization schedules in adults: - Td vaccine, 2-week interval, PCV7, 4-month interval, PPV23 - PCV7, 4-month interval, PPV23 - PPV23 We aim to: - compare the safety profiles of pneumococcal vaccines given on each of the three schedules - compare serotype-specific ELISA antibody response to pneumococcal antigens given on each of the three schedules - compare functional serotype-specific antibody responses to pneumococcal antigens given on each of the three schedules - study the influence of diphtheria antibody levels at the time of pneumococcal conjugate vaccine administration on the magnitude of the immune response to pneumococcal antigens


Criteria:

Exclusion Criteria: - Participation in any other investigational clinical trials except purely observational studies within 4 weeks prior to study start - Any vaccination within 2 weeks prior to first study vaccine - Evidence of systemic or local infection within one week prior to first study vaccine - HIV infection - Renal failure - Receipt of a pneumococcal or Td vaccine within 5 years - Current receipt of therapy for neoplastic disease - Current receipt of immunosuppressive therapy - Terminal illness withlife expectancy less than 3 months


NCT ID:

NCT00164411


Primary Contact:

Principal Investigator
Harry L Keyserling, MD
Emory University


Backup Contact:

N/A


Location Contact:

Atlanta, Georgia 30322
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.